Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer

European Urology

Volumn 56, Issue 2, 2009, Pages 237-244

  Morris, Michael J ^a,b   Huang, Daisy ^b   Kelly, William K ^a,b   Slovin, Susan F ^a,b   Stephenson, Ryan D ^a   Eicher, Caitlin ^a   Delacruz, Anthony ^a   Curley, Tracy ^a   Schwartz, Lawrence H ^a   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Exogenous testosterone; Phase 1 trials; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ANEMIA; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CASTRATION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; HEART ATRIUM FIBRILLATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PAIN; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; URINARY FREQUENCY; URINE RETENTION;

AGED; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT FAILURE;

EID: 67649445878     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.03.073     Document Type: Article

References (21)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Huggins C., Stevens Jr. R.E., and Hodges C.V. Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
3. Kokontis J., Takakura K., Hay N., and Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54 (1994) 1566-1573
4. Kokontis J.M., Hay N., and Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12 (1998) 941-953
5. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation failure in prostate cancer. Cancer Res 57 (1997) 314-319
6. Koivisto P., Visakorpi T., and Kallioniemi O.P. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest 226 Suppl (1996) 57-63
7. Umekita Y., Hiipakka R.A., Kokontis J.M., and Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A 93 (1996) 11802-11807
8. Joly-Pharaboz M.O., Soave M.O., Nicolas B., et al. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J Steroid Biochem Mol Biol 55 (1995) 67-76
9. Fowler Jr. J.E., and Whitmore Jr. W.F. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126 (1981) 372-375
10. Manni A., Bartholomew M., Caplan R., et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6 (1988) 1456-1466
11. Suarez A.J., Lamm D.L., Radwin H.M., Sarosdy M., Clark G., and Osborne C.K. Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol 8 (1982) 261-265
12. Pearson O.H. Discussion of Dr. Huggins' paper: control of cancers of man by endocrinological methods. Cancer Res 17 (1957) 473-479
13. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland: World Health Organization; 1979.
14. Morris M.J., Akhurst T., Larson S.M., et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11 (2005) 3210-3216
15. Rathkopf D., Carducci M.A., Morris M.J., et al. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol 26 (2008) 2959-2965
16. Feltquate D., Nordquist L., Eicher C., et al. Rapid androgen cycling as treatment for patients with prostate cancer. Clin Cancer Res 12 (2006) 7414-7421
17. Zanzonico P.B., Finn R., Pentlow K.S., et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 45 (2004) 1966-1971
18. Larson S.M., Morris M., Gunther I., et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45 (2004) 366-373
19. Shaffer D.R., Leversha M.A., Danila D.C., et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13 (2007) 2023-2029
20. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008) 1148-1159
21. Eggener S.E., Stern J.A., Jain P.M., et al. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 66 (2006) 495-502